GURU.Markets stock price, segment price, and overall market index valuation
The company's share price IGM Biosciences Inc.
International Game Technology (IGT) is a giant in the gambling industry, producing both slot machines and operating lotteries worldwide. Its stock price reflects both the cyclical nature of the gambling industry and the stability of revenue from long-term lottery contracts.
Share prices of companies in the market segment - Pharma immune
IGM Biosciences is a biotechnology company developing a new class of engineered antibodies (IgM) for the treatment of cancer and infectious diseases. We have classified it in the Pharma: Immunology category. The chart below shows how the market values companies with innovative technology platforms.
Broad Market Index - GURU.Markets
IGM Biosciences is an oncology company developing a new class of drugs based on engineered IgM antibodies. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how IGM shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IGMS - Daily change in the company's share price IGM Biosciences Inc.
For IGM Biosciences, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
IGM Biosciences is developing a new class of antibodies (IgM) for cancer treatment. This is a cutting-edge and risky area of biotechnology. The chart below illustrates the high volatility typical of immuno-oncology, providing context for evaluating IGM Biosciences and its innovative approach.
Daily change in the price of a broad market stock, index - GURU.Markets
IGM Biosciences is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization IGM Biosciences Inc.
For IGM Biosciences, the year's performance is a story about the development of a new class of antibodies—IgM. Its 12-month market cap depends entirely on clinical trial data. The success of its approach, which promises stronger target binding, could lead to a breakthrough in the treatment of cancer and autoimmune diseases.
Annual dynamics of market capitalization of the market segment - Pharma immune
IGM Biosciences, Inc. is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IGM Biosciences, a pioneer in the development of engineered IgM antibodies for cancer treatment, represents a breakthrough technology. Its year-over-year market capitalization is a pure bet on science. Positive clinical data can trigger exponential growth, completely ignoring the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization IGM Biosciences Inc.
IGM is an immuno-oncology company developing IgM antibodies. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its unique platform are the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the biotech sector, specifically immuno-oncology. For IGM, with its innovative IgM antibody platform, this is the backdrop. Its movements demonstrate how investor expectations surrounding its unique technology influence its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IGM Biosciences is a biotech company developing a new generation of antibodies (IgM antibodies) for cancer treatment. This is a revolutionary, but high-risk technology. The overall market price has little impact on IGM; its shares are driven by news of clinical trials, and a single success could trigger explosive growth, defying any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization IGM Biosciences Inc.
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for the treatment of cancer and immune diseases. Its weekly stock price is highly volatile and depends on news about clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma immune
IGM Biosciences is developing a new class of antibodies (IgM) for cancer treatment. This is an innovative approach with high potential, but also high risks. The chart will show whether IGM's share price movements are driven by its unique scientific data or reflect overall investor sentiment toward the entire immuno-oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
IGM Biosciences is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
IGMS - Market capitalization of the company IGM Biosciences Inc.
IGM Biosciences' market capitalization reflects investor faith in its unique platform for creating IgM antibodies for cancer treatment. Its volatile price is driven by news of clinical trials. This is a high-risk bet that its new class of antibodies will prove more effective than traditional ones.
IGMS - Share of the company's market capitalization IGM Biosciences Inc. within the market segment - Pharma immune
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for cancer treatment. Its market share in the pharmaceutical sector is very small. Its capitalization is a bet on its unique scientific platform, which, if successful, could lead to the development of more effective oncology drugs.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. IGM Biosciences is a company developing a new generation of immunotherapy based on engineered IgM antibodies. Its approach promises to be more powerful than traditional antibodies. Its market story is a bold scientific bet that its unique platform will lead to a breakthrough in cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
IGM Biosciences is developing a new class of immunotherapeutic drugs based on IgM antibodies, which may be more effective than traditional antibodies. Its market capitalization is a bet on this platform. The chart below shows the economic weight of companies with innovative platforms.
Book value capitalization of the company, segment and market as a whole
IGMS - Book value capitalization of the company IGM Biosciences Inc.
IGM Biosciences's foundation is its cutting-edge scientific platform for creating engineered IgM antibodies for the treatment of cancer and immune diseases. This chart tells the story of a biotech company investing in its unique approach to immunotherapy, building a non-material foundation that could offer advantages over traditional IgG antibodies.
IGMS - Share of the company's book capitalization IGM Biosciences Inc. within the market segment - Pharma immune
IGM Biosciences is developing next-generation antibodies. The chart shows its share of actual R&D assets. These include its laboratories, where a unique platform for producing IgM antibodies, which may be more effective in the fight against cancer, is being developed.
Market segment balance sheet capitalization - Pharma immune
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Their value lies in their unique platform and data. The book value chart shows the value of their R&D centers, which are merely a tool for implementing their scientific idea.
Book value of all companies included in the broad market index - GURU.Markets
IGM Biosciences' assets include laboratories and in-house manufacturing facilities for the creation of a new class of engineered antibodies (IgM) for cancer treatment. The chart shows how the company built this unique scientific and manufacturing platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - IGM Biosciences Inc.
IGM Biosciences is developing a new generation of antibodies for cancer treatment. Its assets represent a unique scientific platform. The chart below visualizes its bet on a scientific breakthrough. Market capitalization, as with many biotech companies, reflects the potential of the technology, not the cost of lab equipment.
Market to book capitalization ratio in a market segment - Pharma immune
IGM Biosciences is developing a new class of engineered antibodies (IgM) that may be more effective in treating cancer than traditional antibodies. Its valuation is based on the potential of its innovative scientific platform. The chart shows a high premium to its stock, reflecting investor hopes for breakthrough drugs.
Market to book capitalization ratio for the market as a whole
IGM Biosciences is developing next-generation antibodies for cancer treatment. Its value lies in its unique scientific platform. This chart demonstrates that the company's market valuation is based on investors' belief in the breakthrough potential of its technology, creating a huge gap with its current tangible assets.
Debts of the company, segment and market as a whole
IGMS - Company debts IGM Biosciences Inc.
IGM Biosciences is developing a new class of engineered antibodies (IgM) for the treatment of cancer and autoimmune diseases. This chart shows how the company is funding its innovative, yet expensive, research. Raising significant capital from investors and partners is essential to advancing its platform through clinical trials.
Market segment debts - Pharma immune
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. This technology has the potential to be more effective than traditional antibodies. This chart illustrates the enormous financial demands associated with advancing such a breakthrough, yet unproven, platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio IGM Biosciences Inc.
IGM Biosciences is a biotech company developing a new class of antibodies. This chart shows its financial structure. For a company working on a breakthrough but unproven technology, debt is a huge risk. Equity financing is essential.
Market segment debt to market segment book capitalization - Pharma immune
IGM Biosciences is a biopharmaceutical company developing a new class of antibodies (IgM) for cancer treatment. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its innovative and expensive research in this cutting-edge field of immuno-oncology.
Debt to book value of all companies in the market
IGM Biosciences is developing a new class of antibodies (IgM) for cancer treatment. This innovative approach requires lengthy and expensive clinical trials. This graph of total market debt serves as an indicator of investor risk appetite, which directly impacts the company's ability to finance its breakthrough, yet unproven, technologies.
P/E of the company, segment and market as a whole
P/E - IGM Biosciences Inc.
IGM Biosciences is a biotech company developing a new class of therapeutic antibodies (IgM antibodies) for cancer treatment. This chart reflects investor confidence in its unique scientific platform, which may be more effective than traditional antibodies. Its performance is entirely dependent on clinical trial results.
P/E of the market segment - Pharma immune
IGM Biosciences is a biotech company developing a new class of engineered IgM antibodies for the treatment of cancer and infectious diseases. IgM antibodies have 10 binding sites, potentially making them more effective. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value innovative scientific platforms with high potential.
P/E of the market as a whole
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. IGM's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of engineered antibodies (IgM) for cancer treatment. This chart reflects investor confidence in the potential of this innovative platform. Future profits depend on the success of clinical trials and the demonstration of the advantages of IgM antibodies over existing ones.
%20P%2FE%20IGM%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-IGM-Biosciences-Inc.&v=1772674690723 "Chart of the company's future (projected) P/E IGM Biosciences Inc.")
Future (projected) P/E of the market segment - Pharma immune
IGM Biosciences is a biotechnology company developing a new class of drugs—IgM engineered antibodies—for the treatment of cancer. The chart reflects average expectations for the oncology segment. IGMS's position relative to this benchmark reflects investors' bet that their unique platform will enable the creation of more potent and effective anticancer drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772674690727 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
IGM Biosciences is a biotech company pioneering the development of engineered IgM antibodies for the treatment of cancer and infectious diseases. IgM antibodies have more binding sites than traditional IgG antibodies, which may improve their effectiveness. This chart of overall market expectations shows how willing investors are to fund breakthrough scientific platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772674690745 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM antibodies) for cancer treatment. Its financial outlook is heavily invested in research. Potential profit depends on whether this innovative technology proves superior to traditional antibodies.
Profit of companies in the market segment - Pharma immune
IGM Biosciences is a biopharmaceutical company developing a new class of antibodies—IgM antibodies—for cancer treatment. This is an innovative platform with potentially higher efficacy. This chart shows the overall profitability of the immunopharmaceutical industry, reflecting the investment appetite for fundamentally new technological platforms in the fight against oncology.
Overall market profit
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for cancer treatment. This is a cutting-edge scientific platform. The company's success depends on the results of clinical trials. The positive economic backdrop, visible in this chart, is critical to attracting the massive investment needed to develop such innovative approaches.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company IGM Biosciences Inc.
IGM Biosciences is developing a new class of antibodies (IgM antibodies) for cancer treatment. This chart reflects analysts' speculative expectations regarding the potential of this innovative platform, which may offer more effective ways to combat cancer, but is associated with high development risks.
%20profit%20of%20the%20company%20IGM%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-IGM-Biosciences-Inc.&v=1772674690798 "Graph of future (projected) profit of the company IGM Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
IGM Biosciences is developing a new generation of antibodies (IgM antibodies) for the treatment of cancer and autoimmune diseases. Their unique structure may provide greater efficacy. The company's future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for evaluating IGM's innovative, yet risky, approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772674690809 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
IGM Biosciences is a biotech company developing a new class of antibodies for cancer treatment. Its value is determined by progress in clinical trials and the uniqueness of its scientific platform. This earnings curve has little bearing on the company's prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772674690832 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - IGM Biosciences Inc.
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Its valuation, shown on this chart, is based on the potential of its unique scientific platform. The valuation reflects investor reaction to clinical trial data, which may confirm or refute the benefits of its approach.
P/S market segment - Pharma immune
IGM Biosciences is developing a new class of antibodies (IgM antibodies) for cancer treatment. Future revenue depends on the success of this innovative platform. This pharma chart reflects investor expectations for the potential of IGM technology to create more powerful and effective cancer treatments than standard antibodies.
P/S of the market as a whole
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. These antibodies have more binding domains than traditional IgG, which may improve their effectiveness. This market revenue valuation chart helps understand how investors view this innovative scientific platform and its potential in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of therapeutic antibodies—IgM antibodies—for the treatment of cancer. This chart shows how the market perceives the future commercial potential of its innovative platform. It reflects the belief that its technology may be more effective than traditional IgG antibodies.
%20P%2FS%20IGM%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-IGM-Biosciences-Inc.&v=1772674690885 "The graph of the company's future (projected) P/S IGM Biosciences Inc.")
Future (projected) P/S of the market segment - Pharma immune
IGM Biosciences is a biotechnology company developing a new class of engineered antibodies (IgM) for cancer treatment. The company's valuation is based on investors' belief that its unique technology, which allows antibodies to bind to a wide range of targets, will lead to the creation of more effective cancer treatments, although this comes with significant risks.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772674690894 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for cancer treatment. It is an innovative scientific platform. In the context of the overall revenue projections shown in the chart, IGM represents a venture investment in the future of immuno-oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772674690908 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales IGM Biosciences Inc.
IGM Biosciences is a clinical-stage biotechnology company developing a new class of antibodies (IgM) for the treatment of cancer and infectious diseases. The company currently has no commercial products, and its revenue, reflected in the chart, comes from upfront fees from partners.
Sales of companies in the market segment - Pharma immune
IGM Biosciences (IGMS) is a biotechnology company developing a new class of antibodies—engineered IgM antibodies—for cancer treatment. These antibodies have 10 binding sites, making them potentially more effective. This figure reflects revenue in the immunological pharmaceutical sector. IGM's platform has the potential to revolutionize cancer therapy.
Overall market sales
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Its future depends on the success of its innovative platform. This pattern of overall economic activity impacts the availability of capital for the biotech sector. During growth periods, investors are more willing to fund companies with breakthrough, yet early-stage, technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for the treatment of cancer and infectious diseases. Future revenue depends on the success of clinical trials of its innovative platform. This chart reflects analyst forecasts, which essentially assess the commercial potential of its cutting-edge scientific technology in oncology.
%20sales%20of%20the%20company%20IGM%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-IGM-Biosciences-Inc.&v=1772674690977 "Schedule of future (projected) sales of the company IGM Biosciences Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
IGM Biosciences is a biopharmaceutical company developing a new class of antibodies (IgM) for cancer treatment. This graph shows the potential future revenue from their innovative platform. This is an analyst's perspective on the commercial prospects of this cutting-edge approach in immuno-oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772674690997 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
IGM Biosciences is developing a new class of antibodies (IgM antibodies) for cancer treatment that may be more effective than traditional IgG antibodies. This is a cutting-edge scientific approach. This graph reflects the overall investment climate, and IGM's progress in clinical trials is a bet on an innovative platform that could lead to a new generation of immunotherapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772674691032 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for the treatment of cancer and autoimmune diseases. Its financial performance reflects significant investment in this unique scientific platform. The chart shows current profitability as an investment in the development of potentially more powerful and effective drugs.
Market segment marginality - Pharma immune
IGM Biosciences is a clinical-stage biotechnology company developing a new class of antibodies (IgM antibodies) for the treatment of cancer and infectious diseases. This chart reflects its operating expenses. Future profitability depends on the success of its innovative platform and clinical programs.
Market marginality as a whole
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. It is at the forefront of immuno-oncology. This total return chart reflects investor appetite for breakthrough but risky technologies. During periods of economic growth, funding for such innovative platforms becomes more accessible.
Employees in the company, segment and market as a whole
Number of employees in the company IGM Biosciences Inc.
IGM Biosciences is a biotechnology company developing a new class of engineered antibodies (IgM) for cancer treatment. These antibodies are larger and more potent than traditional ones. This graph shows the team of scientists working on this cutting-edge platform, aiming to create more effective immunotherapies.
Share of the company's employees IGM Biosciences Inc. within the market segment - Pharma immune
IGM Biosciences is at the forefront of biotechnology, developing a new class of antibodies (IgM) for cancer treatment. This complex scientific endeavor requires a team of highly qualified researchers. This chart illustrates the amount of intellectual capital the company is investing in its unique scientific platform, striving to create more potent oncology drugs.
Number of employees in the market segment - Pharma immune
IGM Biosciences is developing a new class of antibodies (IgM) for cancer treatment. This graph, showing activity in the immunopharmaceuticals sector, illustrates the ongoing search for more effective treatments. For IGM, with its unique platform, growth in this field signifies recognition of the potential of their approach, which may be more powerful than traditional antibodies.
Number of employees in the market as a whole
IGM Biosciences is a biotech company developing a new class of antibodies (IgM antibodies) for cancer treatment. This is a cutting-edge scientific field requiring significant investment. The growth in overall employment shown in this chart reflects a healthy economy, where investors and large pharmaceutical companies are willing to fund breakthrough, yet risky, R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company IGM Biosciences Inc. (IGMS)
IGM Biosciences (IGMS) is a biotech company developing a new class of antibodies (IgM) for cancer treatment. This is a cutting-edge R&D company. This chart shows that the company's entire market value is derived from its unique scientific platform and pipeline. The value per employee is high because it is not tied to physical production.
%20of%20the%20company%20IGM%20Biosciences%20Inc.%20(IGMS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-IGM-Biosciences-Inc.-IGMS&v=1772674691206 "Chart of market capitalization per employee (in thousands of dollars) of the company IGM Biosciences Inc. (IGMS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
IGM Biosciences is developing a new class of antibodies for cancer treatment. In biotech, market capitalization reflects the potential of a breakthrough scientific platform. This chart shows the enormous future value the market is placing on the work of its research team, which could change approaches to immunotherapy.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772674691222 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. It is a cutting-edge scientific platform. This chart for IGM Biosciences illustrates how biotech companies developing fundamentally new classes of drugs can have colossal market capitalization per employee, reflecting their belief in their scientific breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772674691229 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company IGM Biosciences Inc. (IGMS)
IGM Biosciences is a biotech R&D company developing a new class of antibodies (IgM) for cancer treatment. The company is unprofitable. This graph will show a negative value—the loss per scientist. This reflects the high cost of research in this innovative field.
%20Chart%20IGM%20Biosciences%20Inc.%20(IGMS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-IGM-Biosciences-Inc.-IGMS&v=1772674691246 "Company Profit Per Employee (in thousands of dollars) Chart IGM Biosciences Inc. (IGMS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
IGM Biosciences is a biotechnology company developing a new class of antibodies (IgM) for cancer treatment. In advanced immuno-oncology, the productivity of the scientific team is critical. This chart shows the potential value generated by each employee, which is an indicator of the effectiveness of investment in this unique scientific platform.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772674691264 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. They believe IgM antibodies may be more effective than traditional ones. This chart, showing the market average profit per employee, provides important context. It illustrates how high the stakes are in biotech, where a single successful R&D platform can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772674691272 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee IGM Biosciences Inc. (IGMS)
IGM Biosciences is a biotech company developing a new class of antibodies (IgM) for cancer treatment. Being in clinical trials, it has no commercial revenue. The chart will show zero, emphasizing that its value lies in the potential of its innovative scientific platform to create more powerful drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-IGM-Biosciences-Inc.-IGMS&v=1772674691275 "Sales chart per company employee IGM Biosciences Inc. (IGMS)")
Sales per employee in the market segment - Pharma immune
IGM Biosciences (IGMS) is a biotech company developing a new class of antibodies (IgM) for the treatment of cancer and autoimmune diseases. This chart shows the average income per employee in the sector. It is important for assessing R&D efficiency and capital utilization compared to other companies working on antibodies.
Sales per employee for the market as a whole
IGM Biosciences (IGMS) is a biotechnology company developing a new class of antibodies (IgM antibodies) for cancer treatment. These antibodies are believed to be more effective than traditional IgG antibodies. The company has no commercial revenue. This near-zero figure reflects the investment in the team of scientists working on this innovative R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company IGM Biosciences Inc. (IGMS)
IGM Biosciences (IGMS) is a biotech company developing a new class of antibodies (IgM) for cancer treatment. This is an innovative but highly complex platform. This chart shows short interest. The high bearish bets reflect investor concerns about manufacturing complexities and safety risks associated with these large molecules, as well as high cash burn. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-IGM-Biosciences-Inc.-IGMS&v=1772674691301 "Short Shares Chart for the Company IGM Biosciences Inc. (IGMS)")
Shares shorted by market segment - Pharma immune
IGM Biosciences (IGMS) is developing a new generation of antibodies (IgM) for the treatment of cancer and autoimmune diseases. The chart below represents a general short position in the biotech sector. It demonstrates investor skepticism regarding the success of new, unproven technology platforms.
Shares shorted by the overall market
IGM Biosciences is developing a new platform of engineered antibodies (IgM) for cancer treatment. This is complex and expensive science. This chart illustrates the general fear. When investors are pessimistic, they are unwilling to fund R&D, which could take 10 years. They see IGMS as a money-burner and a binary risk, preferring to sell the stock.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator IGM Biosciences Inc. (IGMS)
IGM Biosciences is a biotech company developing a new class of drugs—engineered IgM antibodies, which are larger and more potent than conventional ones. This is R&D at the cutting edge of science. This chart "heats up" on news of partnerships (like with Sanofi) or positive data, reflecting the hype surrounding the platform.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-IGM-Biosciences-Inc.-IGMS&v=1772674691349 "RSI 14 indicator chart for the company's stock IGM Biosciences Inc. (IGMS)")
RSI 14 Market Segment - Pharma immune
IGM Biosciences is a biopharmaceutical company developing a new class of drugs—engineered IgM antibodies. These antibodies are larger than conventional IgG antibodies and, in theory, may be more effective against cancer. This chart measures the overall momentum in the immunology biotech sector. It clearly shows when this entire niche is overhyped or oversold.
RSI 14 for the overall market
IGM Biosciences (IGMS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IGMS (IGM Biosciences Inc.)
IGM Biosciences is a biotech company developing a new generation of immunotherapy—engineered IgM antibodies, which are (theoretically) more potent than standard IgG. This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their faith in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IGMS-IGM-Biosciences-Inc.&v=1772674691409 "A chart showing analyst consensus forecasts for the expected stock price. IGMS (IGM Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price IGMS (IGM Biosciences Inc.)
IGM Biosciences (IGMS) is a biotech company developing "super antibodies" (IgM). Their technology is a bet on creating more potent cancer immunotherapy. This chart shows how far the current share price differs from its "fair" value. It reflects the "venture capital" valuation of analysts for this complex yet groundbreaking R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IGMS-IGM-Biosciences-Inc.&v=1772674691477 "A chart showing the difference between the consensus forecast and the actual stock price. IGMS (IGM Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
IGM Biosciences is betting on a "bigger" weapon against cancer. The company is engineering IgM antibodies, which are much larger than standard drugs, in hopes of a more powerful attack on tumors. This chart reflects the collective opinion of the *entire* immunopharmacology sector. It shows whether experts are optimistic about new R&D platforms.
Analysts' consensus forecast for the overall market share price
IGM Biosciences is a biotech company developing a new class of drugs (IgM antibodies) for cancer immunotherapy. This is a high-risk sector. This chart reflects the overall risk appetite in the market. For IGMS, a clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index IGM Biosciences Inc.
IGM is an R&D machine for IgM. Their specialty isn't conventional antibodies (IgG), but an R&D platform for creating IgM-based therapies—giant (5 times larger) antibodies that (in theory) can attack cancer (immuno-oncology) much more effectively. This chart is a pure R&D barometer of faith/fear. It reflects the market's assessment of their (futuristic) science and their (risky) clinical data.
AKIMA Market Segment Index - Pharma immune
IGM Biosciences is an immuno-oncology company with a unique approach. Instead of conventional antibodies (IgG), they create super-antibodies (IgM) that have 10 arms to bind to cancer cells. This chart compares their composite index to the sector, showing how their IgM platform outperforms the competition.
The AKIM Index for the overall market
IGM Biosciences is a biotech company developing a new class of IgM antibodies for the treatment of cancer and autoimmune diseases. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this unique antibody platform.
